Stance Capital’s Gilead Sciences GILD Stock Holding History

Stance Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.33M	Sell	9,541 -1,731	-15%	-$242K	0.65%	67
2025 Q4	$1.38M	Sell	11,272 -817	-7%	-$99.3K	0.51%	82
2025 Q3	$1.34M	Buy	12,089 +264	+2%	+$30K	0.49%	93
2025 Q2	$1.31M	Buy	+11,825	New	+$1.26M	0.49%	111
2025 Q1	–	Sell	-8	Closed	-$739	–	141
2024 Q4	$739	Buy	+8	New	+$720	﹤0.01%	234

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Stance Capital's GILD Position: Q1 2026 in Review

Stance Capital reduced its Gilead Sciences (GILD) stake by 15% in Q1 2026, selling an estimated $242K and leaving 9,541 shares worth $1.33M. The position accounts for 0.65% of the portfolio, ranked #67.

Stance Capital first reported a position in GILD in Q4 2024 and has held it in 5 quarters since. The position peaked at $1.38M in Q4 2025. 2,310 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Stance Capital held 9,541 shares of Gilead Sciences worth $1.33M as of Q1 2026.
Stance Capital sold 1,731 Gilead Sciences shares in Q1 2026, an estimated $242K.
Gilead Sciences made up 0.65% of Stance Capital's portfolio in Q1 2026, its #67 holding.
Stance Capital first reported a position in Gilead Sciences in Q4 2024 and has held it in 5 quarters since.
Stance Capital's Gilead Sciences position peaked at $1.38M in Q4 2025.
2,310 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Stance Capital's 13F filing for Q1 2026, filed 14 May 2026.